Shareholders of WuXi XDC Cayman (HKG:2268) will meet on Oct. 25 to vote on the proposed revision of the annual caps under a 2023 agreement with controlling shareholder WuXi Biologics (Cayman), a Wednesday bourse filing said.
The contract under discussion is an antibodies master services agreement between the parties valid from Nov. 17, 2023, to Dec. 31, 2025.
The company is proposing to increase the annual caps for the years ending Dec. 31, 2024 and Dec. 31, 2025, to 2 billion yuan each from the current figures of 1.01 billion yuan and 895 million yuan, respectively.
Shares of the company closed nearly 9% higher on Wednesday.
Price (HKD): $22.55, Change: $-2.1, Percent Change: -8.52%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。